Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate for GVHD Prophylaxis in Myeloablative Unrelated Donor Transplantation
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia in Remission; Blasts 5 Percent or Less of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogen ous Leukemia, BCR-ABL1 Positive; Donor; Minimal Residual Disease; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Recurrent Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leuk emia; Therapy-Related Acute Myeloid Leukemia Interventions: Biological: Anti-Thymocyte Globulin; Drug: Busulfan; Drug: Cyclophosphamide; Drug: Cyclosporine; Drug: Fludarabine Phosphate; Drug: Methotrexate; Procedure: Peripheral Blood Stem Cell Transplantation; Other: Quality-of-Life Assessment; Other: Questionnaire Adm inistration; Drug: Tacrolimus; Radiation: Total-Body Irradiation Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chronic Leukemia | Leukemia | Lymphoma | Methotrexate | Myelodysplastic Syndrome | Prograf | Restasis | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants